A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss

A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss

The treatment landscape of metastatic castration-resistant prostate cancer (mCRPC) has dramatically improved over the last decade; however, patients with visceral metastases are still faced with poor outcomes. Phosphatase and tensin homolog (PTEN) loss is observed in 40%–60% of mCRPC patients and is...

Full description

Bibliographic Details
Main Authors: Zin W. Myint, Derek B. Allison, Carleton S. Ellis
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
metastatic castration refractory prostate cancer
PI3K/AKT pathway
carboplatin
abiraterone acetate
ATM/Chk2/p53 signal pathway
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.731002/full

Similar Items

Similar Items